[HTML][HTML] Immunogenicity and safety of an adjuvanted inactivated polio vaccine, IPV-Al, following vaccination in children at 2, 4, 6 and at 15–18 months
X Sáez-Llorens, B Thierry-Carstensen, LS Stoey… - Vaccine, 2020 - Elsevier
Background Availability of affordable inactivated polio vaccines (IPV) is of major importance
to meet the increasing global supply needs. The results presented here demonstrate non …
to meet the increasing global supply needs. The results presented here demonstrate non …
[HTML][HTML] Immunogenicity and safety of an adjuvanted inactivated polio vaccine, IPV-Al, compared to standard IPV: A phase 3 observer-blinded, randomised, controlled …
LC Bravo, JC Carlos, SR Gatchalian, MEB Montellano… - Vaccine, 2020 - Elsevier
Background A dose-sparing inactivated polio vaccine (IPV-Al), obtained by adsorption of
inactivated virus to an aluminium hydroxide adjuvant, can help mitigate global supply and …
inactivated virus to an aluminium hydroxide adjuvant, can help mitigate global supply and …
[HTML][HTML] Persistence of protective anti-poliovirus antibody levels in 4-year-old children previously primed with Picovax®, a trivalent, aluminium-adjuvanted reduced …
X Sáez-Llorens, M Chan, R DeAntonio, T Petersen… - Vaccine, 2022 - Elsevier
Background To meet the demand for effective and affordable inactivated polio vaccines
(IPVs), a reduced dose, aluminium hydroxide (Al (OH) 3)-adjuvanted IPV vaccine was …
(IPVs), a reduced dose, aluminium hydroxide (Al (OH) 3)-adjuvanted IPV vaccine was …
[HTML][HTML] First-in-human safety and immunogenicity investigations of three adjuvanted reduced dose inactivated poliovirus vaccines (IPV-Al SSI) compared to full dose …
LM Lindgren, PN Tingskov, AH Justesen… - Vaccine, 2017 - Elsevier
Background There is a demand of affordable IPV in the World. Statens Serum Institut (SSI)
has developed three reduced dose IPV formulations adsorbed to aluminium hydroxide; 1/3 …
has developed three reduced dose IPV formulations adsorbed to aluminium hydroxide; 1/3 …
Immunogenicity and safety of three aluminium hydroxide adjuvanted vaccines with reduced doses of inactivated polio vaccine (IPV-Al) compared with standard IPV in …
L Rivera, RS Pedersen, L Peña, KJ Olsen… - The Lancet Infectious …, 2017 - thelancet.com
Background Cost and supply constraints are key challenges in the use of inactivated polio
vaccine (IPV). Dose reduction through adsorption to aluminium hydroxide (Al) is a promising …
vaccine (IPV). Dose reduction through adsorption to aluminium hydroxide (Al) is a promising …
[HTML][HTML] Primary and booster vaccination with an inactivated poliovirus vaccine (IPV) is immunogenic and well-tolerated in infants and toddlers in China
R Li, CG Li, Y Li, Y Liu, H Zhao, X Chen, S Kuriyakose… - Vaccine, 2016 - Elsevier
Introduction Replacing live-attenuated oral poliovirus vaccines (OPV) with inactivated
poliovirus vaccines (IPV) is part of the global strategy to eradicate poliomyelitis. China was …
poliovirus vaccines (IPV) is part of the global strategy to eradicate poliomyelitis. China was …
Assessing the immunogenicity of three different inactivated polio vaccine schedules for use after oral polio vaccine cessation, an open label, phase IV, randomized …
Background After global oral poliovirus vaccine (OPV) cessation, the Strategic Advisory
Group of Experts on Immunization (SAGE) currently recommends a two-dose schedule of …
Group of Experts on Immunization (SAGE) currently recommends a two-dose schedule of …
Immunogenicity and effectiveness of routine immunization with 1 or 2 doses of inactivated poliovirus vaccine: systematic review and meta-analysis
NC Grassly - The Journal of infectious diseases, 2014 - academic.oup.com
Abstract Background. The World Health Organization has recommended that all 124
countries currently using only oral poliovirus vaccine (OPV) introduce at least 1 dose of …
countries currently using only oral poliovirus vaccine (OPV) introduce at least 1 dose of …
Safety and immunogenicity of inactivated poliovirus vaccine schedules for the post-eradication era: a randomised open-label, multicentre, phase 3, non-inferiority trial
AS Bandyopadhyay, C Gast, L Rivera… - The Lancet Infectious …, 2021 - thelancet.com
Background Following the global eradication of wild poliovirus, countries using live
attenuated oral poliovirus vaccines will transition to exclusive use of inactivated poliovirus …
attenuated oral poliovirus vaccines will transition to exclusive use of inactivated poliovirus …
Immunogenicity of full and fractional dose of inactivated poliovirus vaccine for use in routine immunisation and outbreak response: an open-label, randomised …
CJ Snider, K Zaman, CF Estivariz, M Yunus… - The Lancet, 2019 - thelancet.com
Background Intradermal administration of fractional inactivated poliovirus vaccine (fIPV) is a
dose-sparing alternative to the intramuscular full dose. We aimed to compare the …
dose-sparing alternative to the intramuscular full dose. We aimed to compare the …